semaglutide 75 units 7.2mg achieved 20.7% weight loss in STEP UP obesity trial A stronger 7.2 mg dose

These insights are particularly relevant in the Middle East, where obesity rates remain high across both adult and paediatric populations.

This can lead to feelings of fullness, which may help with weight loss, but it can also cause gastrointestinal discomfort in some people, potentially leading to gastritis or worsening of existing conditions

Indian pharma firms have periodically faced regulatory actions from global agencies such as the U.S

[1] Differential diagnoses [2] Intra-abdominal abscess Pancreatic pseudocyst Cystic neoplasm Pseudosacculation (e.g., in Crohn disease) Management [1] [2] No treatment is required for asymptomatic individuals